Non-alcoholic Fatty Liver Disease, Obesity
Conditions
Brief summary
Nonalcoholic fatty liver disease (NAFLD) is associated to obesity, metabolic syndrome and genetic predisposition: specific variants of the genes PNPLA3 and TM6SF2 are the most involved. Also biochemical mechanisms that affect the metabolic flexibility need to be better clarified. It is known that a dietary intervention, accompanied by a physical personalized training, reduce either the hepatic fat content either insulin resistance. Therefore, the aim of the study is to evaluate metabolic flexibility in obese NAFLD subjects taking in account the presence or absence of PNPLA3 and TM6SF2 polymorphism and the histopathological diagnosis of either simple steatosis or nonalcoholic steatohepatitis (NASH). The composition of gut microbiota will be also evaluated. Finally, two distinct healthy dietary profiles accompanied by a personalized physical training, will be tested to comprehend whether and how healthy diets could operate in the clinical treatment of NAFLD and related conditions.
Detailed description
Nonalcoholic fatty liver disease (NAFLD) is frequently associated to obesity and metabolic syndrome. In NAFLD, a heritable component to disease susceptibility has been demonstrated: the variants of the genes PNPLA3 and TM6SF2 are the most involved genetic determinants. To date, biochemical mechanisms that affect the metabolic flexibility in obese NAFLD subjects, in presence or absence of genetic susceptibility, need to be better clarified. Different studies demonstrated that a dietary intervention, accompanied by a physical personalized training, significantly reduce either the hepatic fat content either insulin resistance in overweight and obese subjects, independently of weight loss. On these bases, the aim of the study is to evaluate metabolic flexibility in obese NAFLD subjects taking in account their genetics (presence or absence of PNPLA3 and TM6SF2 polymorphisms) and the histopathological diagnosis of either simple steatosis or nonalcoholic steatohepatitis (NASH). In addition, the composition of gut microbiota will be evaluated. Finally, in this study, two distinct healthy dietary profiles accompanied by a personalized physical training, will be tested in order to comprehend whether and how healthy diets could be effective not only in the prevention, but also in the clinical treatment of NAFLD and other related conditions.
Interventions
DIETARY_SUPPLEMENTMediterranean diet
In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol \<300 mg/day, dietary fiber 25 g/day.
DIETARY_SUPPLEMENTLow fat diet
In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
OTHERAerobic exercise
A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type).
Sponsors
Bambino Gesù Hospital and Research Institute
Università degli studi di Roma Foro Italico
Göteborg University
University of Roma La Sapienza
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Nonalcoholic fatty liver disease (NAFLD) is associated to obesity, metabolic syndrome and genetic predisposition: specific variants of the genes PNPLA3 and TM6SF2 are the most involved. Also biochemical mechanisms that affect the metabolic flexibility need to be better clarified. It is known that a dietary intervention and a physical personalized training, reduce either the hepatic fat content either insulin resistance. Therefore, the aim of the study is to evaluate metabolic flexibility in obese NAFLD subjects taking in account the presence or absence of PNPLA3 and TM6SF2 polymorphism and the histopathological diagnosis of either simple steatosis or nonalcoholic steatohepatitis (NASH). The composition of gut microbiota will be also evaluated. Finally, two distinct healthy dietary profiles accompanied by a personalized physical training, will be tested to comprehend whether and how healthy diets could operate in the clinical treatment of NAFLD and related conditions.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* body mass index (BMI) \> 30 Kg/m2 and \< 40 Kg/m2; * Caucasian Italian subjects * hepatic steatosis according with ultrasonographic Hamaguchi's criteria and/or hypertransaminasemia (ALT \>30 IU/L in men and \>20 IU/L in women)
Exclusion criteria
* any malignant disease during the last 5 years; * any inflammatory or autoimmune disease; * corticosteroids for systemic use; * renal failure (GFR\<90 ml/min); * heart failure (NYHA classes II-IV); * history of viral or autoimmune liver disease; * any cause cirrhosis; * excessive alcohol intake (\>140g/week for men and 70g/week for women); * participation in a reducing-weight program in the last 3 months; * level of physical activity higher than 3 METs; * therapy with antibiotics during the last 3 months; * bile salts, cholestyramine during the last 6 months before enrollment; * previous cholecystectomy; * gallbladder disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cholesterol assessment | baseline | total cholesterol, HDL- cholesterol, LDL- cholesterol levels reported as mg/dl |
| triglycerides assessment | baseline | tryglicerides levels reported as mg/dl |
| metabolic flexibility variation in liver function; | baseline | alanine aminotransferase (ALT) \[U/L\] , aspartate aminotransferase (AST) \[UI/L\] |
| Waist circumference measurements; | baseline | waist circumference reported as cm |
| anthropometric measurements; | baseline | Body mass index reported as kg/m\^2 |
| Ultrasonographic examination; | baseline | Liver ultrasonography according with criteria by Hamaguchi |
| Glucidic profile | baseline | fasting glucose reported as mg/dl |
| Insulinemia | baseline | insulin reported as µU/mL |
Countries
Italy
Outcome results
None listed